Ritholtz Wealth Management Purchases Shares of 2,200 Humana Inc. $HUM

Ritholtz Wealth Management purchased a new stake in shares of Humana Inc. (NYSE:HUM) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 2,200 shares of the insurance provider’s stock, valued at approximately $538,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of HUM. Cary Street Partners Investment Advisory LLC raised its position in Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after purchasing an additional 46 shares during the last quarter. Garde Capital Inc. bought a new position in shares of Humana in the 1st quarter worth approximately $36,000. Zions Bancorporation National Association UT bought a new position in shares of Humana in the 1st quarter worth approximately $37,000. Ransom Advisory Ltd bought a new position in shares of Humana in the 1st quarter worth approximately $66,000. Finally, Transamerica Financial Advisors LLC raised its position in shares of Humana by 1,027.6% in the 1st quarter. Transamerica Financial Advisors LLC now owns 327 shares of the insurance provider’s stock worth $87,000 after acquiring an additional 298 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Humana stock opened at $275.00 on Monday. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $33.07 billion, a P/E ratio of 21.11, a PEG ratio of 1.61 and a beta of 0.42. The stock’s 50 day moving average is $280.54 and its 200 day moving average is $258.14. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $315.35.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to analysts’ expectations of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. On average, equities research analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.3%. The ex-dividend date is Friday, September 26th. Humana’s dividend payout ratio (DPR) is currently 27.17%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on HUM shares. Wolfe Research increased their target price on Humana from $283.00 to $313.00 and gave the stock an “outperform” rating in a research report on Monday, October 6th. Guggenheim reissued a “buy” rating on shares of Humana in a research report on Friday, October 3rd. Sanford C. Bernstein increased their target price on Humana from $269.00 to $341.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Truist Financial set a $300.00 target price on Humana in a research report on Tuesday, October 14th. Finally, Wall Street Zen lowered Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Eight investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $297.58.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.